Pioneer Pharmaceutical Biotechnology (00399) plans to acquire Conflux assets

Zhitongcaijing · 06/30 15:41

Zhitong Finance App News, Pilot Pharmaceutical Biotechnology (00399) issued an announcement. On June 30, 2025, the company (as the buyer) signed a memorandum of understanding with the seller (Northwestern Foundation) and Conflux regarding the potential acquisition of all shares of the target company, provided that the target company completes the acquisition of Conflux assets in accordance with the agreement with the company.

Conflux is a limited company incorporated in Hong Kong, China, mainly engaged in developing blockchain technology. The target company is a limited company to be incorporated by the seller in the Cayman Islands and wholly owned by the seller.

The company is actively exploring new business opportunities, diversifying revenue sources, and implementing strategic plans to improve performance. The company plans to expand its business to blockchain technology and enter the digital innovation industry. The Memorandum of Understanding indicates the company's commitment to enter the digital innovation industry through potential acquisitions to develop this new business segment. The company believes that this move will not only diversify the Group's business, but also bring new profit growth impetus to the Group.